What are the trends and outcomes of transcatheter aortic valve replacement (TAVR) in patients with myeloproliferative neoplasms compared to matched controls?
20 June 2026 (08:30 - 18:00)
Organised by: 

Abstract
Slides
About the speaker

Zionsville (United States of America)
40 More presentations in this session
Absence of detectable cardiotoxicity with L-Annamycin despite high cumulative anthracycline exposure
Mr S. Waymack (Blacksburg, US)
Mr A. Alshahrani (Riyadh, SA)
Doctor M. Merhi (Berlin, DE)
Doctor M. Elelmi (Tunis, TN)
Doctor E. Bennour Ep Rabah (Tunis, TN)
Access the full session
The Event
ESC Cardio-Oncology 2026
20 June 2026
08:30 CET

